Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma
- Morra F.
- Merolla F.
- D'Abbiero D.
- Ilardi G.
- Campione S.
- Monaco R.
- Guggino G.
- Ambrosio F.
- Staibano S.
- Cerrato A.
- Visconti R.
- Celetti A.
Publication date
January 2019
DOIAbstract
CCDC6 (coiled-coil domain containing 6) is a player of the HR response to DNA damage and has been predicted to interact with BAP1, another HR-DNA repair gene highly mutated in Malignant Pleural Mesothelioma (MPM), an aggressive cancer with poor prognosis. CCDC6 levels are modulated by the deubiquitinase USP7, and CCDC6 defects have been reported in several tumors determining PARP-inhibitors sensitivity. Our aim was to investigate the functional role of CCDC6 in MPM carcinogenesis and response to PARP-inhibitors
Add to ORKG